KEYNOTE-054: Analysis of Crossover and Rechallenge With Pembrolizumab in Recurrent Patients After Complete Resection of High-Risk Stage III Melanoma

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
In KEYNOTE-054 Part 2, PFS and ORR after recurrence and crossover to pembrolizumab were similar to previous studies of immune checkpoint therapy for advanced melanoma, but pembrolizumab rechallenge had minimal activity.
Format: Microsoft PowerPoint (.ppt)
File Size: 2.39 MB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings